Form 4: PepGen Inc. Executive Michelle L. Mellion Reports Stock Option Grant

Michelle L. Mellion, SVP of Clinical Development at PepGen Inc., reports the acquisition of stock options.

Summary

• On March 1, 2024, Michelle L. Mellion, SVP of Clinical Development at PepGen Inc., reported a transaction related to derivative securities.
• Mellion acquired stock options (right to buy) for 83,000 shares of common stock at an exercise price of $16.62.
• The options vest as follows: 25% on March 1, 2025, and the remaining 75% in 36 equal monthly installments, contingent upon continued service with the company.
• Following the reported transaction, Mellion beneficially owns 83,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a stock option grant. However, the grant can be viewed as a positive sign of the company's confidence in its future, hence the slightly positive sentiment score.

Positives

• The granting of stock options to a key executive like the SVP of Clinical Development can be seen as a positive incentive for continued service and alignment with company goals.

Industry Context

This is a standard practice for companies to incentivize and retain key employees, especially in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a common form of compensation in the biotechnology industry, used to align the interests of employees with those of shareholders.
• Companies like Amgen, Biogen, and Gilead Sciences routinely grant stock options to their executives as part of their compensation packages.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could potentially incentivize the executive to work towards increasing shareholder value.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates